Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm.
Long-term vascular complications still represent the main cause of morbidity and mortality in diabetic patients. Although randomized long-term clinical studies comparing the effects of conventional and intensive therapy have demonstrated a clear link between hyperglycemia and the development of complications of diabetes, they have not defined the mechanism through which excess glucose results in tissue damage. Evidence has accumulated indicating that oxidative stress may play a key role in the etiology of diabetic complications. Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to human vascular disease. Their formation in vivo seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation. Enhanced urinary excretion of 8-iso-PGF(2alpha) has been described in association with both type 1 and type 2 diabetes mellitus, and correlates with impaired glycemic control. Besides providing a likely noninvasive index of lipid peroxidation in this setting, measurements of specific F(2) isoprostanes in urine may provide a sensitive biochemical end point for dose-finding studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF(2alpha) in vitro suggest that it and other isoeicosanoids may modulate the functional consequences of lipid peroxidation in diabetes, evidence that this is likely in vivo remains inadequate at this time.
Mezzetti
A
A
Department of Medicine and Aging, University of Chieti "G D'Annunzio" School of Medicine, Chieti, Italy. mezzetti@unich.it
Cipollone
F
F
Cuccurullo
F
F
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D001095:Arachidonic Acids / Q000378:metabolism; D001161:Arteriosclerosis / Q000378:metabolism; D015415:Biomarkers / Q000652:urine; D003327:Coronary Disease / Q000175:diagnosis* / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism; D019587:Dietary Supplements; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000652:urine; D028441:F2-Isoprostanes; D006801:Humans; D006943:Hyperglycemia / Q000378:metabolism; D015227:Lipid Peroxidation; D018384:Oxidative Stress; D020033:Protein Isoforms / Q000378:metabolism; D014810:Vitamin E / Q000627:therapeutic use
D000975:Antioxidants; D001095:Arachidonic Acids; D015415:Biomarkers; D028441:F2-Isoprostanes; D020033:Protein Isoforms; D014810:Vitamin E; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost